The Covid-19 pandemic has spread continuously during its dark days. It has affected millions of lives and took thousands of ots tolls worldwide. Hence, solving this problem became a priority for most countries in the world, and trying to produce an effective vaccine was one of the most important actions of countries to control this disease.
Iran was not exempt from this issue and took important measures in this field. In line with the general movement of the country, the Humimmune Biotech, which has been engaged in research and development of the technical knowledge of making recombinant viruses, especially the measles virus, for the past few years, launched two projects to make a new generation corona vaccine based on viruses.
One of these projects, which is being carried out in collaboration with Biosan Pharmed, is the production of a corona vaccine, based on the recombinant measles virus. Now, after several months of round-the-clock efforts, the specialists of Humimmune Biotechnology in cooperation with Biosan Pharmed Company have succeeded in making a sample of this new generation Covid19 vaccine.
It should be noted that the technology on which the production of this vaccine is based on is very advanced and this technology is only available to a few technological groups in the world, and with the production of this recombinant virus in the Humimmune Biotechnology, the Islamic Republic of Iran officially entered this area. It is worth mentioning that this vaccine candidate will be available on the market after conducting pre-clinical and clinical studies that will last for several months if necessary approvals are obtained.
Another project that is being carried out under the supervision and with the investment and cooperation of the Biotechnology Development Headquarters of the Scientific and Technological office of Vice Presidency of Islamic Republic of Iran, is the project of developing a covid vaccine based on Ad5 recombinant adenovirus, whose laboratory research and development stages are in It is progressing now.